Caris Life Sciences, Inc.
CAIHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Caris Life Sciences, Inc. focuses on Biotechnology services and products. Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. The company carries a $9.04B market cap, placing it firmly in the mid-cap category. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Market Cap
$9.04B
Beta
—
P/E (TTM)
18.71
P/E (Fwd)
86.04
EPS (TTM)
$1.71
EPS (Fwd)
$0.37
ROE
20.1%
ROA
8.8%
Cash
$793.1M
Total Debt
$452.4M
Free CF
$63.3M
52W Change
3.0%
Annual Financials
Cash vs Debt
Where CAI stands vs its 150-day and 200-day moving averages
As of the October 6, 2026 close, CAI finished 50.74% above its 150-day moving average ($20.16) and 43.15% above its 200-day moving average ($21.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CAI overbought or oversold?
At the October 6, 2026 close, CAI's RSI(14) was 57.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $793.1M in cash comfortably exceeding the $452.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $63.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 20.1% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $258.5M (2022) to $812.0M (2025), reflecting a 214% increase over the period.
As with any equity investment, CAI carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CAI.